Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19 by B. Tilocca et al.
  
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 
granted for free by Elsevier for as long as the COVID-19 resource centre 
remains active. 
 
lable at ScienceDirect
Microbes and Infection 22 (2020) 182e187Contents lists avaiMicrobes and Infection
journal homepage: www.elsevier .com/locate/micinfOriginal articleImmunoinformatic analysis of the SARS-CoV-2 envelope protein as a
strategy to assess cross-protection against COVID-19
Bruno Tilocca a, Alessio Soggiu b, c, Maurizio Sanguinetti d, e, Gabriele Babini f,
Flavio De Maio d, e, Domenico Britti a, Alfonso Zecconi b, Luigi Bonizzi b,
Andrea Urbani d, e, **, Paola Roncada a, *
a Department of Health Science, University “Magna Græcia” of Catanzaro, Viale Europa, 88100, Catanzaro, Italy
b Department of Biomedical, Surgical and Dental Sciencese One Health Unit, University of Milano, Via Celoria n10, 20133, Milano, Italy
c Department of Veterinary Medicine, University of Milano, Via dell’Universita 6, 26900, Lodi, Italy
d Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Universita Cattolica del Sacro Cuore, Largo Francesco Vito 1,
00168, Roma, Italy
e Dipartimento di Scienze di laboratorio e infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli, Largo A. Gemelli 8, 00168, Roma, Italy
f Dipartimento Scienze della Salute della Donna, del Bambino e di Sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli 8, 00168,
Roma, Italya r t i c l e i n f o
Article history:
Received 5 May 2020
Accepted 19 May 2020
Available online 21 May 2020
Keywords:
SARS-CoV-2
COVID-19
Coronavirus
Immunoinformatics
Diagnosis
One-health* Corresponding author. Viale Europa, 88100, Catan
** Corresponding author. Largo San Vito n.1, 00168,
E-mail addresses: andrea.urbani@unicatt.it (A.
(P. Roncada).
https://doi.org/10.1016/j.micinf.2020.05.013
1286-4579/© 2020 Institut Pasteur. Published by Elsea b s t r a c t
Envelope protein of coronaviruses is a structural protein existing in both monomeric and homo-
pentameric form. It has been related to a multitude of roles including virus infection, replication,
dissemination and immune response stimulation. In the present study, we employed an immu-
noinformatic approach to investigate the major immunogenic domains of the SARS-CoV-2 envelope
protein and map them among the homologue proteins of coronaviruses with tropism for animal species
that are closely inter-related with the human beings population all over the world. Also, when not
available, we predicted the envelope protein structural folding and mapped SARS-CoV-2 epitopes. En-
velope sequences alignment provides evidence of high sequence homology for some of the investigated
virus specimens; while the structural mapping of epitopes resulted in the interesting maintenance of the
structural folding and epitope sequence localization also in the envelope proteins scoring a lower
alignment score. In line with the One-Health approach, our evidences provide a molecular structural
rationale for a potential role of taxonomically related coronaviruses in conferring protection from SARS-
CoV-2 infection and identifying potential candidates for the development of diagnostic tools and
prophylactic-oriented strategies.
© 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.The begin of 2020 has seen the rapid diffusion of a novel beta-
coronavirus strain, SARS-CoV-2, as the causal agent of the COVID-
19. Over boundaries diffusion of SARS-CoV-2 resulted in the
pandemic declaration by WHO and the consequent adoption of a
series of containment measures to promptly control the virus
spread and COVID-19 diffusion [1,2]. To date, COVID-19 diffusion
seems to be approaching to an end in the outbreak epicentre and
the early affected countries (e.g. Italy), whereas lately affected
countries are likely to diminish the COVID-19 incidence in the veryzaro, Italy.
Roma, Italy.
Urbani), roncada@unicz.it
vier Masson SAS. All rights reservenear future [3,4]. Nevertheless, prospective studies are predicting
the cyclic recurrence of epidemic waves of SARS-CoV-2 over a very
short period of time [3], raising the need for the timely develop-
ment of effective diagnostic tools and prophylactic strategies, other
than the design of adequate guidelines for patients’ treatments in
the diverse stages of the infection.
The circulating SARS-CoV-2 is a novel strain of the coronavirus
genus. Coronaviruses are spherical viruses of large dimension with
a positive-sense unsegmented RNA genome of approximately 30
kilobases. Coronavirus specimens are already known in veterinary
medicine since capable of infecting an extended spectrum of both
wild (e.g. bat, palm civet) and domestic animals (e.g. bovine)
including the companion ones (e.g. dogs). The infection is
commonly manifested as respiratory illness along with other mildd.
Table 1
Selected virus overview. The table lists the viral specimens employed in this study
along with the relative details.
Virus NCBI TaxID NCBI Genome Protein GI
SARS-CoV-2 2697049 NC_045512.2 YP_009724392.1
Bat CoV RaTG13 693998 MN996532 QHR63302.1
SARS-CoV 694009 NC_004718.3 NP_828854.1
Pangolin CoV 2708335 MT084071 QIQ54050.1
Camel CoV 1335626 MK967708 QGV13485.1
MERS-CoV 1335626 NC_019843.3 YP_009047209.1
Dromedarius CoV 1335626 MH259486 QCI31485.1
H-Enteric CoV 166124 FJ415324 ACJ35487.1
Canine CoV 215681 KX432213 AQT26502.1
Bovine CoV 11128 NC_003045 NP_150081.1
Avian CoV 11120 NC_001451 NP_040834.1
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coronaviruses have also represented a public health issuewithmild
manifestation commonly referable to flu-like symptoms. Excep-
tions are represented by the SARS-CoV epidemic in China in 2002
[7] and the Middle-East Respiratory Syndrome coronavirus (MERS-
CoV) registered in Saudi Arabia in 2012 [8] when the more severe
manifestation of the infection occurred as a consequence of
increased pathogenicity of the circulating viral specimens. Unfor-
tunately, no vaccines or therapy were made available from the
previous outbreaks and the recent warningly predictions justify the
overwhelming effort being performed worldwide under diverse
perspectives.
According to the One-Health concept, extending the target of
studies to the major animals the humans are most frequently
interacting with would provide valuable information for a better
comprehension of the virus biology and pathogenetic mechanisms.
This is of pivotal importance for the adequate design of effective
diagnostic tools and control measures. Elucidating immunological
properties of the circulating SARS-CoV-2 along with the tracking of
the epitopes distribution among coronaviruses with tropism for the
most common synanthropic animals might provide a clear depic-
tion of the co-shared epitopes. Such approachmight, from one side,
suggest the occurrence of partial protection arising from the
human-animal interrelation while, on the other hand, it might
provide a valuable list of epitope candidates to be used for the
differential diagnosis of SARS-CoV-2 infection. Investigation of the
major viral structural proteins (i.e. Spike, Membrane, Nucleocapsid
and Envelope) provides unevaluable knowledge for a comprehen-
sive depiction of the antigenic determinants of the circulating virus
[9e11]. Our previous studies investigated epitope diffusion of the
Spike and Nucleocapsid SARS-CoV-2 proteins, highlighting some
epitopes sequences as conserved among a restricted group of
taxonomically-related specimens while other epitopes sequences
were shared between coronavirus with tropism for the animal’s
human are continuously interacting with [9,10].
Along with Spike (S) and Nucleocapsid (NC) protein, Envelope
(E) is a structural protein involved in diverse phases of the virus
infection. E protein of SARS-CoV-2 is a 75 amino acids long protein
existing in both monomeric and homo-pentameric form. Approx-
imately 20 copies of the protein have been found in the viral par-
ticle and previous mutagenesis-based studies demonstrated its
pivotal role in the onset and development of the viral infection [12].
Specifically, E protein lacking virions are associated with incapa-
bility of infecting host cell or very low viral titers [13]. Other
functions have been predicted for E protein within the infected
cells. E protein localizes within the secretory pathways at the
interspace between the endoplasmic reticulum and Golgi appa-
ratus. Here, the arrangement of the hydrophobic transmembrane
domain into a homo-pentamer has been predicted to form an ion
channel (i.e. virioporin) in several coronavirus strains. Whereas,
PDZ binding domain (PBD) at the C-terminal of the amino acid
polymer is supposed to hinder the host cell functionality to favor
viral replication and dissemination within the host body [12,14,15].
Besides its multifunctional properties, E protein is also highly
immunogenic attracting the attention of diverse research groups
that target this protein for the development of antigen-based
studies including those aimed at developing immunodiagnostic
tools and prophylactic oriented studies [11,16]. To date, immu-
noinformatic is among the most promising approaches to survey
the antigenic determinants of novel and unknown molecules. It is
based on the use of computational resources (e.g. software, algo-
rithms and statistic models) to investigate protein sequences and
predict the antigenicity of molecule portions (epitope prediction). It
is based on different parameters such as the physicochemical
properties of the amino acids, their spatial localization, and thecomplementarity and affinity with models of the immune response
effectors such as the B-cells and T-cells [16e18].
In the present study, we employed the immunoinformatic
approach to evaluate the antigenicity potential of the SARS-CoV-2 E
protein. Major epitopes of the SARS-CoV-2 E protein are predicted
and resulting sequences compared with the homologue immuno-
logical domains of taxonomically related coronaviruses with
tropism for the synanthropic animal species that are most
commonly interacting with the human beings population all over
the world. The epitope mapping and comparison among the cross-
species presented in the present studymight provide a keystone for
assessing the potential occurrence of partial protection arising from
the human-animal interaction besides their importance for the
development of immunodiagnostic tools and/or the design further
efficient prophylactic-oriented studies.
1. Material and methods
1.1. Data collection and protein sequence processing
The virus species and accession number of the proteins
employed in this survey are provided in Table 1. Envelope protein
sequences were retrieved from NCBI Protein repository (https://
www.ncbi.nlm.nih.gov/protein/) and UniProt KB (https://www.
uniprot.org).
Protein sequences as of Table 1 were analyzed via the Basic Local
Alignment Search Tool for protein sequences (pBLAST) [19]. This
tool implements BLOSUM62 algorithm to compare protein se-
quences and calculates the statistical significance of matches as
means of e-values. Multiple sequence alignment was performed by
keeping default settings. Only statistically significant matches were
considered for drawing the similarity tree. Fast minimum evolution
algorithm was employed to produce a tree from given distances
between sequences by setting a maximum fraction of mismatch
between pairs of sequences of 0.75.
1.2. Envelope protein epitopes prediction
SARS-CoV-2 E protein epitopes prediction was performed by
means of the IEDB prediction tools. Both B-cell and T-cell pre-
dictions were performed. Prediction of linear B-cell epitopes was
performed through BepiPred algorithm. It predicts the location of
linear B-cell epitopes using a combination of a hidden Markov
model and a propensity scale method [20]. Both default threshold
settings (0.350) and a lower threshold value (0.250) were used. T-
cell epitopes were predicted by using the artificial neural network
(ANN) algorithm. The list of epitopes binding to MHC class I and
class II molecules was obtained via MHCeI Binding and MHCeII
Binding tools respectively. In line with a very recent study [16],
Fig. 1. Phylogenetic classification of the selected coronaviruses on the basis of the
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selected and immunogenic domains binding to MHC I and II mol-
ecules scoring respectively a median inhibitory concentration
(IC50) equal or less than 100 and 1000, were employed for the
sequence alignment against the E protein sequence of the taxo-
nomically related coronaviruses with tropism for other synan-
thropic and/or domestic animals. The BLAST-based alignment was
performed using BLOSUM62 algorithm to compare protein se-
quences and calculate the statistical significance of matches as
means of e-values. Only the best hits were considered for each virus
and hits with alignment length minor or equal to 4 amino acids
were manually removed.
1.3. Tridimensional (3D) folding prediction of the E proteins
Tridimensional structure of the SARS-CoV E protein has been
recently elucidated and made available in the RCSB PDB database
under the identifier 5  29 [21]. Acknowledged the high similarity
occurring among the E protein sequences of SARS-CoV, SARS CoV-2,
bat CoV and pangolin CoV we considered 5  29 as unique refer-
ence structure for the E proteins of these viral specimens. The E
proteins of the other coronaviruses whose 3D structure has not yet
been elucidated were computationally predicted by using homol-
ogy modeling tool [22]. Predicted models were exported as PDB
files to be employed in the next step of structural mapping of the
epitopes.
1.4. Structural mapping of epitopes to PDB structures
The protein epitopes of SARS-CoV E proteinweremapped on the
available PDB structure (5  29) whereas predicted PDB files were
used for the proteins whose high definition crystallographic
structure was not available. PyMOL Molecular Graphics System,
Version 2.3.4 (Schr€odinger, LLC.) was employed for the structural
mapping of the selected epitopes over the coronavirus E protein
structures.
2. Results
The full protein sequence of the E proteins from the selected
coronavirus specimens was employed to assess the virus similarity
on the basis of the conserved protein sequences. The multiple
sequence alignment of the entire E protein sequences reveals that
SARS-CoV-2 E protein is 100% identical to the bat coronavirus and
the pangolin coronavirus counterparts as also supported by the
nucleotide-based investigations performed at the level of the
whole genome sequence. Slightly less than 95% of sequence simi-
larity is observed between the query sequence (i.e. SARS-CoV-2 E
protein) and the E protein sequence of SARS-CoV, the causal agent
of the previous outbreak. Minor sequence similarity was observed
in regard to the E protein of the causal agent of MERS, MERS-CoV,Table 2
Whole protein sequence alignment between the selected coronavirus representatives.
Virus Protein GI Identity (%)
Pangolin CoV QIQ54050.1 100
Bat CoV QHR63302.1 100
SARS-CoV NP_828854.1 94.737
Dromedarius CoV QCI31485.1 36
MERS-CoV YP_009047209.1 36
Camel CoV QGV13485.1 36
Canine CoV AQT26502.1 30.769
Bovine CoV NP_150081.1 30.769
H-Enteric CoV ACJ35487.1 30.769
Avian CoV NP_040834.1 20and the (Camelus bactrianus) and dromedaries (Camelus drome-
darius) coronavirus, scoring an amino acid sequence similarity
below 40%. Finally, the whole sequence similarity between the
SARS-CoV-2 E protein and the homologues from the human enteric
coronavirus as well as thosewith tropism for the bovine and dogs is
slightly below 31%. Even minor is the sequence similarity observed
with the chicken coronavirus, where 20% of the overall protein
sequence is shared with SARS-CoV-2, Table 2.
Depiction of the virus specimens by means of the distance
matrix calculated from the E protein sequences comparison is in
line with the observation summarized in Table 2. Indeed, the bat
coronavirus RaTG13, pangolin coronavirus and the circulating
SARS-CoV-2 are grouped in the same clade, supporting the occur-
rence of a very strong similarity. These are followed by the SARS-
CoV, whose E protein sequence enables a close classification be-
tween the past and the current epidemic causal agents. A separate
clade is reserved to the E protein of the MERS-CoV and the coro-
naviruses with tropism for camels and dromedaries. These are
displayed as the sister group of another clade including the human
enteric coronavirus along with the coronaviruses with tropism for
dog and bovine; whilst avian coronavirus is placed apart since
featured by a lower degree of similarity with respect to SARS-CoV-2
E protein sequence, Fig. 1.
Once assessed the overall sequence similarity among the diverse
coronavirus representatives, the major immunogenic domains of
the SARS-CoV-2 E protein were predicted by following an immu-
noinformatic approach. Prediction of the B-cell epitopes failed to
predict epitopes sequence that meets the quality filter prefixed
(score threshold of 0.350 and minimum 10 amino acid length). A
further prediction employing a lower score threshold (0.250) pre-
dicted one epitope sequence, but it was subsequently discarded
since redundant with the prediction of T-cell epitopes.Alignment length Mismatches e-value
75 0 2.15E-51
75 0 2.15E-51
76 3 2.22E-47
75 44 4.01E-12
75 44 4.01E-12
75 44 4.01E-12
39 27 3.30E-06
39 27 3.40E-06
39 27 3.40E-06
75 53 0.066
envelope protein sequence.
Table 3
Selected envelope protein epitopes.
Epitope Virus % Identity Length MHC Class Alignment length Position e-value
SLVKPSFYV Pangolin CoV 100 9 I 9 50e58 7.71E-08
Bat CoV 100 I 9 50e58 7.71E-08
SARS-CoV-2 100 I 9 50e58 7.71E-08
SARS-CoV 77.8 I 9 50e58 2.32E-04
Bovine CoV 80 I 5 56e60 0.048
H-Enteric CoV 80 I 5 56e60 0.048
Canine CoV 80 I 5 56e60 0.048
LTALRLCAY SARS-CoV 100 9 I 9 34e42 4.94E-08
Pangolin CoV 100 I 9 34e42 4.95E-08
Bat CoV 100 I 9 34e42 4.95E-08
SARS-CoV-2 100 I 9 34e42 4.95E-08
Dromedarius CoV 85.7 I 7 34e40 0.002
Camel CoV 85.7 I 7 34e40 0.002
MERS-CoV 85.7 I 7 34e40 0.002
Avian CoV 100 I 4 15e18 0.09
LVKPSFYVY Pangolin CoV 100 9 I 9 51e59 1.93E-08
Bat CoV 100 I 9 51e59 1.93E-08
SARS-CoV-2 100 I 9 51e59 1.93E-08
SARS-CoV 77.8 I 9 51e59 5.70E-05
Bovine CoV 66.7 I 6 56e61 0.023
H-Enteric CoV 66.7 I 6 56e61 0.023
Canine CoV 66.7 I 6 56e61 0.023
KPSFYVY
SRVKNLNS
Pangolin CoV 100 15 II 15 53e67 2.11E-14
Bat CoV 100 II 15 53e67 2.11E-14
SARS-CoV-2 100 II 15 53e67 2.11E-14
SARS-CoV 86.7 II 15 53e67 5.88E-11
Bovine CoV 62.5 II 8 56e63 0.004
H-Enteric CoV 62.5 II 8 56e63 0.004
Canine CoV 62.5 II 8 56e63 0.004
LLVTLAIL
TALRLCA
Pangolin CoV 100 15 II 15 27e41 2.37E-13
Bat CoV 100 II 15 27e41 2.37E-13
SARS-CoV-2 100 II 15 27e41 2.37E-13
SARS-CoV 100 II 15 27e41 2.37E-13
Dromedarius CoV 71.5 II 14 27e40 1.06E-05
Camel CoV 71.5 II 14 27e40 1.06E-05
MERS-CoV 71.5 II 14 27e40 1.06E-05
Avian CoV 100 II 4 15e18 0.27
CNIVNVS
LVKPSFYV
Pangolin CoV 100 15 II 15 44e58 1.49E-14
Bat CoV 100 II 15 44e58 1.49E-14
SARS-CoV-2 100 II 15 44e58 1.49E-14
SARS-CoV 86.7 II 15 44e58 4.17E-11
H-Enteric CoV 50 II 16 49e60 0.023
Canine CoV 50 II 16 49e60 0.023
LIVNSVLLF
LAFVVFLLV
TLAILTAL
RLCAY
SARS-CoV 100 31 II 31 12e42 7.76E-16
Pangolin CoV 100 II 31 12e42 8.65E-16
Bat CoV 100 II 31 12e42 8.65E-16
SARS-CoV-2 100 II 31 12e42 8.65E-16
Dromedarius CoV 71.5 II 14 27e40 0.01
Camel CoV 71.5 II 14 27e40 0.01
Canine CoV 35.7 II 14 29e42 1.1
Bovine CoV 35.7 II 14 29e42 1.2
H-Enteric CoV 35.7 II 14 29e42 1.2
Avian CoV 40 II 10 20e29 78
B. Tilocca et al. / Microbes and Infection 22 (2020) 182e187 185Prediction of T-cell epitopes sequences capable of binding both
class I and class II MHC are listed in Table 3 and the supplementary
file S1.
Mapping of the epitopes between the selected coronavirus with
tropism for synanthropic and/or domestic animals reveal that all
the predicted epitopes are “shared” between the closest relatives in
taxonomic terms, complete identity. This consideration includes
the SARS-CoV that, although showing matches for all the predicted
epitope sequences, scored a minor percentage of similarity in a
handful of epitopes predicted to be capable of class II MHC binding.
Nevertheless, some epitopes are also shared between the
circulating SARS-CoV-2 and the causal agent of a previous outbreak
such as the MERS-CoV and the related camel-CoV and
dromedaries-CoV. Despite the relatively weak similarity observed
at the level of the whole E protein sequence (Fig. 1, Table 2), bovineCoV, canine CoV, human enteric CoV and avian-CoV are also sharing
interesting epitope sequences, as supported by the epitope length
and the relative e-value (Table 3). In addition, structure prediction
of the E protein of the human enteric coronavirus, bovine corona-
virus and dog coronavirus resulted in a very similar 3D structure
among each other and, in turn, with the high-definition 3D struc-
ture of SARS-CoV-2 E protein suggesting that the low sequence
similarity might not hinder the antigenic properties of the E protein
from diverse coronaviruses (Fig. 2).
Structural mapping of selected epitopes highlights a plurality of
epitopes adjacent each other, forming a conformational immuno-
genic domain of the protein that might exist either in its mono-
meric form or associate as a homo-pentamer (Fig. 2). Interestingly,
structural mapping of the SARS-CoV-2 E epitopes in the 3D struc-
ture of the bovine CoV, dog CoV and the human enteric CoV
Fig. 2. Tridimensional structure of envelope proteins from coronavirus representatives and epitope mapping. Epitope sequences are coloured as follow: blue: LIVNSVLL-
FLAFVVFLLVTLAILTALRLCAY; cyan: LLVTLAILTALRLCA; green: LTALRLCAY; olive green: CNIVNVSLVKPSFYV; red: SLVKPSFYV; orange: LVKPSFYVYSRVKNL; yellow: LVKPSFYVY;
magenta: KPSFYVYSRVKNLNS. A) Homopentameric form of the envelope protein from SARS-CoV (PDB database identifier 5  29). Selected epitopes sequences are mapped in each
monomer. B) Monomer for of the SARS-CoV-2 E protein coloured according to the selected epitopes. C) Predicted 3D structure (monomeric form) of the bovine CoV, dog CoV and
human enteric CoV. Selected epitopes sequences are mapped in the monomer. D) Consensus structural mapping of the selected epitopes by overlaying the monomeric form of the E
proteins coloured as in the panels B and C.
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immunogenic domains, suggesting a potential interest for confer-
ring partial cross-protection against the circulating SARS-CoV-2.3. Discussion
The ongoing COVID-19 is a pandemic issue that solicited interest
and expertise from the global scientific community, on the attempt
to elucidating multiple aspects of this novel virus and drawing the
most appropriate measures for rapid and effective control of the
SARS-CoV-2 spread and patients treatments. According to the One
Health approach, extending the focus of studies to the environment
surrounding humans and the animals they are frequently inter-
acting with might represent a valid strategy for obtaining an all-
embracing view on this phenomenon and provide suggestions for
novel research directions e.g. aimed at developing innovative
diagnostic and/or prophylactic interventions.
In the present study, we employed an immunoinformatic
approach to investigate the major SARS-CoV-2 E proteindistribution among the pool of animals most frequently interacting
with the human population all over the world. Coronavirus mem-
bers were already known as the responsible agents of past epi-
demics in both humans and animals [7,8]. This aspect has also been
taken into account while choosing the viral specimens to be
included in this survey. Being all selected coronavirus taxonomi-
cally related, we believe that some immunological features can be
shared between these viruses with tropism for different animals
and, at the same, time this can be exploited for obtaining a partial
cross-protection against the circulating SARS-CoV-2. Such thought
might be partially supported by previous studies reporting early
detection of IgG in the very first phase of the infection along with
the heterogeneous clinical manifestation of the SARS-CoV-2 in-
fections, other than preventing epitopes-exposed subjects from the
severe form of COVID-19 [23]. On the other hand, the “shared”
immunostimulant domains can be used for the design of a more
accurate and efficient immunodiagnostic tool, enabling a detailed
tracking of the infected patients and the fair discrimination of the
SARS-CoV-2 infected ones from the others that came in contact
B. Tilocca et al. / Microbes and Infection 22 (2020) 182e187 187with the antigens carried by other coronaviruses. This might be of
great help, especially among the population of individuals diag-
nosed as infected but without clinical signs.
Structural proteins are among themost antigenic components of
the coronaviruses. Previous studies performed by this group
already highlighted the diffusion of the Spike and Nucleocapsid
protein of the circulating SARS-CoV-2 among the taxonomically
related coronaviruses [9,10]. Envelope protein is featured by mul-
tiple functions in the diverse phases of the infection. Although
present in a relatively low number of copies per viral particle, it has
shown important immunostimulant activity. Multiple sequence
alignment of the E protein sequences reveals bat coronavirus and
pangolin coronaviruses as the most similar viral specimens to
SARS-CoV-2. Although very high, SARS-CoV has scored a minor
sequence homology than the E protein of the virus with tropism for
bat and pangolin. This is also true when analyzing the diffusion of
the predicted SARS-CoV-2 sequence epitopes and the relative
matching scores. Although all predicted sequence epitopes have
been matched in the SARS-CoV E protein sequence, some of the
epitopes capable of binding the class II MHC molecules scored a
lower identity percentage when compared with bat and pangolin
coronavirus, supporting our hypothesis that investigating synan-
thropic and/or domestic animalsmight be a promising strategy that
provides interesting research suggestions.
Envelope proteins of the human enteric coronavirus along with
the bovine coronavirus and canine respiratory coronavirus have
scored a low percentage of identity at the level of the whole E
protein sequences. Nevertheless, also these viral specimens are
sharing a number of SARS-CoV-2 epitopes in their E protein amino
acid chain. Also, the structural comparison performed between the
newly released high-definition 3D structure of the SARS-CoV E-
protein and the predicted 3D model of the E protein of human
enteric-, bovine- and canine-coronaviruses confirms the main-
taining of the conformational structure of the overall monomer
regardless the amino acid sequence of each protein.
Moreover, the structural mapping of the predicted epitopes
sequences highlighted the adjacent mapping of some of the SARS-
CoV-2 E domains suggesting the most immunogenic portion of the
E protein in both its monomeric and homopentameric forms. In
addition, structural mapping of some of the investigated epitopes
in the human enteric CoV, bovine CoV and canine CoV demon-
strated a consensus in both the location of the sequence along the
aminoacidic chain and their 3D folding. Such an evidence suggests,
once again, their potential immunogenicity and possible implica-
tion for the design of immunodiagnostic tools and/or the plan of
prophylactic-oriented investigations, even though showing
reduced sequence homology with the SARS-CoV-2 E counterpart.
To conclude, we strongly believe that synergistic cooperation
elucidating multiple aspects of the virus biology and pathology
enables the success in a fast and effective control of the SARS-CoV-2
infections. The thorough survey of the SARS-CoV-2 epitopes and
their mapping in the diverse geographical areas and among the
major animal species involved in animalehuman interactions
represents a valuable approach. Providing such knowledge is
indeed of pivotal importance for fighting the current COVID-19
pandemic through innovative solutions such as the personalized
medicine and the design of specific community-based prophylactic
measures.Declaration of Competing Interest
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None.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.micinf.2020.05.013.References
[1] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A,
Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared
with SARS-CoV-1. N Engl J Med 2020;382:1564e7.
[2] Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020;130:
2202e5.
[3] Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the
transmission dynamics of SARS-CoV-2 through the postpandemic period.
Science 2020. https://doi.org/10.1126/science.abb5793 [Online ahead of
print].
[4] Schlickeiser R, Schlickeiser F. A Gaussian model for the time development of
the Sars-Cov-2 corona pandemic disease. Predictions for Germany made on
March 30, 2020. 03.31.20048942 MedRxiv 2020. https://doi.org/10.1101/
2020.03.31.20048942 [Online ahead of print].
[5] Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication,
and pathogenesis. J Med Virol 2020;92:418e23.
[6] Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microb Infect
2020;22:72e3.
[7] Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses:
the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.
J Autoimmun 2020;3:102434.
[8] Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet
2015;386:995e1007.
[9] Tilocca B, Soggiu A, Musella V, Britti D, Sanguinetti M, Urbani A, et al. Mo-
lecular basis of COVID-19 relationships in different species: a one health
perspective. Microb Infect 2020. https://doi.org/10.1016/j.micinf.2020.03.002
[Online ahead of print].
[10] Tilocca B, Soggiu A, Sanguinetti M, Musella V, Britti D, Bonizzi L, et al.
Comparative computational analysis of SARS-CoV-2 nucleocapsid protein
epitopes in taxonomically related coronaviruses. Microb Infect 2020. https://
doi.org/10.1016/j.micinf.2020.04.002 [Online ahead of print].
[11] Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Pascarella S. Sars-CoV-2
Envelope and Membrane proteins : differences from closely related proteins
linked to cross-species transmission ? Preprints 2020. https://doi.org/
10.20944/preprints202004.0089.v1. 2020040089, [Online ahead of print].
[12] Stodola JK, Dubois G, Le Coupanec A, Desforges M, Talbot PJ. The OC43 human
coronavirus envelope protein is critical for infectious virus production and
propagation in neuronal cells and is a determinant of neurovirulence and CNS
pathology. Virology 2018;515:134e49.
[13] Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge.
Virol J 2019;16:69.
[14] Nieto-Torres JL, DeDiego ML, Alvarez E, Jimenez-Guarde~no JM, Regla-Nava JA,
Llorente M, et al. Subcellular location and topology of severe acute respiratory
syndrome coronavirus envelope protein. Virology 2011;415:69e82.
[15] Torres J, Wang J, Parthasarathy K, Liu DX. The transmembrane oligomers of
coronavirus protein E. Biophys J 2005;88:1283e90.
[16] Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS,
Shantier SW, et al. Design of multi epitope-based peptide vaccine against E
protein of human 2019-nCoV: an immunoinformatics approach. 02.04.934232
BioRxiv 2020. https://doi.org/10.1101/2020.02.04.934232. 2020.02.04.
934232, [Online ahead of print].
[17] Backert L, Kohlbacher O. Immunoinformatics and epitope prediction in the
age of genomic medicine. Genome Med 2015;7:119.
[18] Tomar N, De RK. Immunoinformatics: a brief review. Methods Mol Biol
2014;1184:23e55.
[19] Altschul SF, Wootton JC, Gertz EM, Agarwala R, Morgulis A, Sch€affer AA, et al.
Protein database searches using compositionally adjusted substitution
matrices. FEBS J 2005;272:5101e9.
[20] Larsen JEP, Lund O, Nielsen M. Improved method for predicting linear B-cell
epitopes. Immunome Res 2006;2:2.
[21] Surya W, Li Y, Torres J. Structural model of the SARS coronavirus E channel in
LMPG micelles. Biochim Biophys Acta Biomembr 2018;1860:1309e17.
[22] Guex N, Peitsch MC, Schwede T. Automated comparative protein structure
modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective.
Electrophoresis 2009;30:S162e73.
[23] Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-
CoV-2 in patients of novel coronavirus disease. Clinical Infectious Diseases;
2019. https://doi.org/10.1093/cid/ciaa344. ciaa344.
